ARCHIVES

FDA advisors vote against recommending Johnson & Johnson’s Zarnestra for treatment of AML in the elderly.

This article is from The Cancer Letter archive.

Vol. 31 No. 18 | May 6, 2005

Download PDF Visit The Full Archive

Related Articles

DCPC Planning 10 More Prevention Fellowship Awards

August 14, 1987

House Committee Investigates Marketing Practices Of Amgen And J&J For ESAs.

April 4, 2008

DCCP Board Okays New, Recompeting Contracts Worth $4.6 Million In ‘81

October 17, 1980

NCAB, Hammer Agree On how 41 Billion To Be Handled: No String Attached

October 14, 1988

In Brief: FCRC Committee Loses Chance To influence RFP; Recompetition To Remain On Schedule

November 5, 1976

In Brief: NIH Call For Review Group Nominations Brings 8,000 Names For 400 Vacancies

August 17, 1979